Health Resource Utilization Associated with Skeletal-Related Events in Patients with Advanced Prostate Cancer: A European Subgroup Analysis from an Observational, Multinational Study

被引:7
作者
Bahl, Amit [1 ]
Hoefeler, Herbert [2 ]
Duran, Ignacio [3 ]
Hechmati, Guy [4 ]
Garzon-Rodriguez, Cristina [5 ]
Ashcroft, John [6 ]
Lorusso, Vito [7 ,8 ]
Ghelani, Prayashi [9 ]
Wei, Rachel [10 ]
Thomas, Emma [11 ]
Lueftner, Diana [12 ]
机构
[1] Univ Hosp Bristol, Bristol Royal Infirm, Upper Maudlin St, Bristol BS2 8HW, Avon, England
[2] Res Ctr Ruhr, D-58455 Witten, Germany
[3] Integrated Canc Ctr Clara Campal CIOCC, Madrid 28050, Spain
[4] Amgen Europe GmbH, Hlth Econ, CH-6301 Zug, Switzerland
[5] Inst Oncol Catal ICO IDIBELL, Barcelona 08908, Spain
[6] Pinderfields Gen Hosp, Mid Yorkshire Hosp NHS Trust, Wakefield WF1 4DG, England
[7] Natl Canc Inst IRCCS Giovanni Paolo II, I-70124 Bari, Italy
[8] Oncol Inst ASL, I-573100 Lecce, Italy
[9] Biostat Ovatech Solut, London SW19 2NA, England
[10] Biostat Amgen Inc, Thousand Oaks, CA 91320 USA
[11] Sci Publicat Amgen Europe GmbH, CH-6301 Zug, Switzerland
[12] Charite, Med Hosp Berlin, D-10117 Berlin, Germany
关键词
bone metastases; Europe; health resource utilization; prostate cancer; skeletal-related events;
D O I
10.3390/jcm3030883
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study aimed to increase the understanding of health resource utilization (HRU) associated with skeletal-related events (SREs) occurring in patients with bone metastases secondary to advanced prostate cancer. A total of 120 patients from Germany, Italy, Spain and the United Kingdom were enrolled in this observational study. They had bone metastases secondary to prostate cancer and had experienced at least one SRE in the 97 days before giving informed consent. HRU data were collected retrospectively for 97 days before enrolment and prospectively for up to 18-21 months. HRU, including the number and duration of inpatient hospitalizations, number of outpatient and emergency department visits and procedures, was independently attributed by investigators to an SRE. Of the 222 SREs included in this analysis, 26% were associated with inpatient stays and the mean duration per SRE was 21.4 days (standard deviation (SD) 17.8 days). Overall, 174 SREs (78%) required an outpatient visit and the mean number of visits per SRE was 4.6 (SD 4.6). All SREs are associated with substantial HRU. Preventing SREs in patients with advanced prostate cancer and bone metastases may help to reduce the burden to both patients and European healthcare systems.
引用
收藏
页码:883 / 896
页数:14
相关论文
共 28 条
[1]   Metastatic bone disease: clinical features, pathophysiology and treatment strategies [J].
Coleman, RE .
CANCER TREATMENT REVIEWS, 2001, 27 (03) :165-176
[2]  
Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.3.CO
[3]  
2-Z
[4]   Clinical features of metastatic bone disease and risk of skeletal morbidity [J].
Coleman, Robert E. .
CLINICAL CANCER RESEARCH, 2006, 12 (20) :6243S-6249S
[5]   Impact of skeletal complications on patients' quality of life, mobility, and functional independence [J].
Costa, Luis ;
Badia, Xavier ;
Chow, Edward ;
Lipton, Allan ;
Wardley, Andrew .
SUPPORTIVE CARE IN CANCER, 2008, 16 (08) :879-889
[6]   Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer A French Prospective, Observational, Multicenter Study (GFPC 0601) [J].
Decroisette, Chantal ;
Monnet, Isabelle ;
Berard, Henri ;
Quere, Gilles ;
Le Caer, Herve ;
Bota, Suzanna ;
Audigier-Valette, Clarisse ;
Geriniere, Laurence ;
Vernejoux, Jean-Marc ;
Chouaid, Christos .
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (03) :576-582
[7]   The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer [J].
Delea, T ;
Langer, C ;
McKiernan, J ;
Liss, M ;
Edelsberg, J ;
Brandman, J ;
Sung, J ;
Raut, M ;
Oster, G .
ONCOLOGY, 2004, 67 (5-6) :390-396
[8]  
Delea Thomas, 2006, J Support Oncol, V4, P341
[9]   Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer [J].
DePuy, Venita ;
Anstrom, Kevin J. ;
Castel, Liana D. ;
Schulman, Kevin A. ;
Weinfurt, Kevin P. ;
Saad, Fred .
SUPPORTIVE CARE IN CANCER, 2007, 15 (07) :869-876
[10]  
European Medicines Agency, XGEV DEN SUMM PROD C